STOCK TITAN
  1. Home
  2. News
  3. NRXP

NRX Pharmaceuticals Inc - NRXP STOCK NEWS

Welcome to our dedicated news page for NRX Pharmaceuticals (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on NRX Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NRX Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NRX Pharmaceuticals's position in the market.

News
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) announced Dr. Jonathan Javitt will present at the Ketamine 2024 Conference in Oxford, UK. The conference gathers leading scientists and clinicians worldwide to share knowledge and insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
conferences
-
News
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) will release its Q4 and full year 2023 financial results on March 28, 2024. A conference call to discuss the results and provide a corporate update will be held at 4:30 p.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.87%
Tags
conferences earnings
-
News
NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders
Rhea-AI Summary
NRx Pharmaceuticals, Inc. announces the results of a Special Meeting of Shareholders with 61.4% of eligible shares voted, 94.4% in favor of a proposal for a reverse stock split. Despite efforts to suppress the vote, shareholders showed overwhelming support for the resolution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
News
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
Rhea-AI Summary
NRx Pharmaceuticals authorizes Dividend and Royalty Rights to NRXP Shareholders and warrant holders, distributing 49% of HOPE Therapeutics stock and 1% of Ketamine sales. Proxy voting for special meeting on March 21, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.16%
Tags
none
-
News
NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
Rhea-AI Summary
NRx Pharmaceuticals, Inc. takes action to protect shareholder value by addressing short sellers through proposed changes in corporate name, CUSIP number, and potential reverse split. The Company aims to ensure compliance with Nasdaq listing rules and prevent naked short sales positions in its securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.32%
Tags
none
-
News
NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
Rhea-AI Summary
NRx Pharmaceuticals and HOPE Therapeutics partner with Conversio Health and Nephron Pharmaceuticals to provide IV Ketamine to patients and clinics, aiming to offer high-quality solutions and ensure ongoing supply. The Company is set to receive its first allocation of ketamine by the end of March 2024, with plans to commence sales once technical aspects are finalized.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.06%
Tags
none
News
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Rhea-AI Summary
NRx Pharmaceuticals announces completion of Phase 2b/3 study for NRX-101 in Suicidal Bipolar Depression, triggering potential $4 million milestone payment and further development by partners. Positive data could lead to up to $329 million in milestone payments and royalties. Top-line data expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.69%
Tags
clinical trial
-
News
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share
Rhea-AI Summary
NRx Pharmaceuticals, Inc. received $1.0 million in cash from an existing investor through the sale of approximately 2.7 million shares at $0.38 per share, along with warrants at $0.40 per share. This investment will support the company in reaching milestones in its development pipeline, including data for Suicidal Depression, Suicidal Bipolar Depression, and Chronic Pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.03%
Tags
none
-
News
NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 million
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) announces the pricing of its public offering, generating $1.5 million in gross proceeds. The company plans to use the funds for working capital, debt obligations, and corporate purposes. The offering includes an option for additional shares, with EF Hutton LLC as the book-runner. The company also secured a separate $1 million commitment from an existing investor. The Chairman highlights the strategic use of funds to extend the company's runway, launch HOPE Therapeutics, and service debt obligations. The offering is expected to close on February 28, 2024, subject to customary conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.31%
Tags
offering
News
/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./
Rhea-AI Summary
NRx Pharmaceuticals, Inc. announces the pricing of a $1.5 million underwritten public offering of common stock at $0.30 per share, with plans to use the net proceeds for working capital, general corporate purposes, and debt obligations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.31%
Tags
none
Stock NRXP logo
NRX Pharmaceuticals Inc

Nasdaq:NRXP

NRXP Rankings

#4974 Ranked by Market Cap
#4956 Ranked by Stock Gains
N/A Ranked by Dividends

NRXP Stock Data

49.00M
6.63M
30.04%
4.29%
4.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Delray Beach